Class / Patent application number | Description | Number of patent applications / Date published |
435199000 | Ribonuclease (3.1.4) | 39 |
20080293121 | HUMAN DNASE I HYPERACTIVE VARIANTS - The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive variants of human DNase I. | 11-27-2008 |
20100196989 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof - The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors. | 08-05-2010 |
20100291657 | RIBONUCLEASES IN WHICH AN AMINO ACID SEQUENCE OF A KNOWN RIBONUCLEASE IS PRECEDED BY AT LEAST ONE RESIDUE AT THE N-TERMINUS, AND METHODS OF MAKING THEM RECOMBINANTLY - New RNases, and methods of making them, are disclosed. Each includes an amino acid sequence that is disclosed in U.S. Pat. No. 6,239,257 B1, but that is preceded by a different N-terminus residue or leader sequence. | 11-18-2010 |
20100304463 | RIBONUCLEASE IN WHICH AN AMINO ACID SEQUENCE OF A KNOWN RIBONUCLEASE IS PRECEDED BY A RESIDUE AT THE N-TERMINUS, AND A METHOD OF MAKING IT RECOMBINANTLY - A new RNase, and a method for making it, are disclosed. The RNase has an amino acid sequence that is disclosed in U.S. Pat. No. 6,239,257 B1, but that is preceded by a different N-terminus residue. | 12-02-2010 |
20100317082 | RELATED RIBONUCLEASES IN WHICH AN AMINO ACID SEQUENCE OF A KNOWN RIBONUCLEASE IS PRECEDED BY AT LEAST ONE RESIDUE AT THE N-TERMINUS, AND METHODS OF MAKING THEM RECOMBINANTLY - New RNases, and methods for making them, are disclosed. Each includes an amino acid sequence that is disclosed in U.S. Pat. No. 6,239,257 B1, but that is preceded by a different N-terminus residue or leader sequence. | 12-16-2010 |
20110027857 | Methods of improving the introduction of DNA into bacterial cells - The present invention relates to methods of improving the introduction of DNA into bacterial host cells. | 02-03-2011 |
20110086409 | Surfactant-Based Monolithic Columns, Methods for Making the Same, and Method for Using the Same - A method for making a surfactant-based monolithic column is provided. The method comprises providing a mixture comprising at least one surfactant monomer, at least one crosslinker, at least one initiator, and at least one porogen and polymerizing the mixture to form the surfactant-based monolithic column. The present disclosure also provides a surfactant-based monolithic column, a method for separating molecules, and a process for preparing a surfactant monomer. | 04-14-2011 |
20110287514 | CYTOTOXIC RIBONUCLEASE VARIANTS - This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity. | 11-24-2011 |
20110318811 | COMPOSITIONS AND METHODS OF USING A SYNTHETIC DNASE I - Compositions and method for making and using a synthetic bovine DNase I are disclosed. More particularly, the sbDNase I of the present invention is a versatile enzyme that cleaves DNA nonspecifically to release 5′-phosphorylated nucleotides. The sbDNase I molecules of the present invention find particular use in a wide range of molecular biology applications, including: degradation of contaminating DNA after RNA isolation; RNA clean-up prior to, or in conjunction with, RT-PCR after in vitro transcription; identification of protein binding sequences on DNA (DNase I footprinting); prevention of clumping when handling cultured cells; tissue dissociation and creation of fragmented DNA for in vitro recombination reactions. | 12-29-2011 |
20120070877 | RATIONALLY DESIGNED MEGANUCLEASES WITH ALTERED SEQUENCE SPECIFICITY AND DNA-BINDING AFFINITY - Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research. | 03-22-2012 |
20120100597 | STABILIZED PROTEASE-CONTAINING SOLUTIONS - The present invention provides compositions and methods for purifying RNA-free DNA from a sample. | 04-26-2012 |
20120135498 | Method for Producing Nucleases of a Gram Negative Bacterium While Using a Gram Positive Expression Host - A method for producing a nuclease of a gram negative bacterium or a nuclease preparation containing a nuclease of a gram negative bacterium including expression of the nuclease in a gram positive bacterium and subsequent secretion of the nuclease, as well as a nuclease or a nuclease preparation that can be obtained by this method. | 05-31-2012 |
20120258517 | CYTOLETHAL DISTENDING TOXINS AND DETECTION OF CAMPYLOBACTER BACTERIA USING THE SAME AS A TARGET - The present inventors succeeded in cloning the CDT genes of | 10-11-2012 |
20120258518 | Method for Incorporating Internal Polar and Ionizable Groups in Proteins - Internal polar and ionizable groups are essential for enzymatic catalysis, proton transport, redox reactions, and many other functional properties of proteins. To engineer novel enzymes or to modify the function of existing ones, and to build switches that can be used to modify the stability of proteins in response to changes in pH, it is necessary to introduce polar or ionizable groups or to modify the properties of existing ones. However, internal polar and ionizable groups usually destabilize proteins. The disclosure provides new methods that allow the introduction of polar and ionizable groups into the interior of proteins, as well as new methods for improving the accuracy of pK | 10-11-2012 |
20120309073 | RNAI IN BUDDING YEAST - The invention provides budding yeast that have a functional RNAi pathway. The invention provides RNAi pathway polypeptides derived from budding yeast that have an endogenous RNAi pathway. In some embodiments the invention provides functional budding yeast Dicer polypeptides and variants thereof. In some embodiments the invention provides functional budding yeast Argonaute polypeptides and variants thereof. Also provided are isolated nucleic acids encoding the polypeptides of the invention, vectors comprising such nucleic acids, and methods of making the polypeptides and nucleic acids. The invention further provides genetically engineered cells that comprise a functional RNAi pathway polypeptide derived from budding yeast. In some embodiments such cells lack a functional endogenous RNAi pathway and are genetically engineered to have a functional RNAi pathway by introducing nucleic acid(s) encoding one or more functional RNAi pathway polypeptides derived from budding yeast. The invention provides methods of using RNAi in budding yeast and/or in cells of other types, wherein the cells have been genetically engineered to express one or more RNAi pathway polypeptides of the invention. Also provided are methods of producing siRNA, either in vitro or in vivo, using a Dicer polypeptide derived from budding yeast. | 12-06-2012 |
20120322137 | Cytotoxic Ribonuclease Variants - This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity. | 12-20-2012 |
20130011904 | CYTOTOXIC RIBONUCLEASE VARIANTS - Cytotoxic variants of human ribonuclease 1 (RNase 1) identified through analysis of the interaction between RNase 1 and the human ribonuclease inhibitor (hRI) as defined by the three dimensional (3-D) atomic structure of the RNase1 hRI complex are disclosed. Also disclosed is the 3-D structure of the hRI·RNase 1 complex and methods for designing the RNase 1 variants. | 01-10-2013 |
20130115680 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 05-09-2013 |
20130115681 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 05-09-2013 |
20130122568 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 05-16-2013 |
20130189760 | NOVEL EXTRACELLULARLY SECRETED NUCLEASE - The purpose of the present invention is to provide a nuclease that secretes natural nonpathogenic microorganisms extracellularly, has higher specific activity than conventional nucleases, and is useful in nucleolytic degradation on an industrial scale. This purpose is achieved with an extracellularly secreted nuclease derived from | 07-25-2013 |
20130244304 | Novel Restriction Endonucleases, DNA Encoding These Endonucleases and Methods for Identifying New Endonucleases with the Same or Varied Specificity - Specified restriction endonucleases have been characterized for the first time by their amino acid and DNA sequences. These sequences and those with at least 90% identity thereto have been used as probes in sequence similarity analyses to identify sequence matches in a sequence database that corresponds to novel restriction endonucleases or isoschizomers. The sequence similarity analyses includes selecting a positive sequence match from any sequence producing an expectation value of less than or equal to e-02. | 09-19-2013 |
20130267009 | Rationally-Designed Single-Chain Meganucleases With Non-Palindromic Recognition Sequences - Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence. The invention also relates to methods of producing such meganucleases, and methods of producing recombinant nucleic acids and organisms using such meganucleases. | 10-10-2013 |
20130330805 | Control of Cyanate in Aqueous Urea Solutions by Non-1,2-Ethylene Diamine Like Compounds for the Protection of Protein/Peptide Carbamylation - Embodiments of the present invention generally relate to processing of peptides in urea solutions and substantial prevention of carbamylation of the peptide. | 12-12-2013 |
20140004594 | CYTOTOXIC RIBONUCLEASE VARIANTS | 01-02-2014 |
20140134704 | Antimicrobial Activity Enhancing Agent - An antimicrobial activity enhancing agent for lactoferrin or a lactoferrin hydrolysate, which contains ribonuclease-4 as an active ingredient, and a method for producing an antimicrobial activity enhancing agent for lactoferrin or a lactoferrin hydrolysate, which comprises (a) the step of contacting raw milk with a cation exchange resin to adsorb proteins in the raw milk to the cation exchange resin, (b) the step of washing the cation exchange resin having undergone the adsorption treatment, and flowing an elution solvent to elute a protein fraction having an isoelectric point of 8.0 to 10.0, and (c) the step of subjecting the eluted protein fraction to gel filtration using a gel filtration carrier to collect a fraction of a molecular weight of 30 kDa or less. | 05-15-2014 |
20140154780 | High Fidelity Restriction Endonucleases - Methods and compositions are provided for engineering mutant enzymes with reduced star activity where the mutant enzymes have a fidelity index (FI) in a specified buffer that is greater than the FI of the non-mutated enzyme in the same buffer. | 06-05-2014 |
20140335593 | Cytotoxic Ribonuclease Variants - This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity. | 11-13-2014 |
20150010982 | Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses - The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition. | 01-08-2015 |
20150093802 | ZINC FINGER NUCLEASE FOR THE CFTR GENE AND METHODS OF USE THEREOF - The present invention provides new zinc finger proteins and zinc finger nuclease (ZFNs) that find particular using in repairing the cystic fibrosis transmembrane conductance regulator (CFTR) gene. | 04-02-2015 |
20150099290 | INSERTION OF CHARGE IN THE HYDROPHOBIC INTERIOR OF PROTEINS AS A STRATEGY FOR ENGINEERING PH-SENSITIVE SWITCHES - Methods are provided for engineering non-naturally occurring proteins comprising artificial pH-sensitive conformational switches that respond to a change in pH by causing a global unfolding of the proteins. Non-naturally occurring proteins comprising artificial pH-sensitive conformational switches that respond to a change in pH by causing a global unfolding of the proteins are also provided. | 04-09-2015 |
20150291965 | ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS - The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity. | 10-15-2015 |
20150315557 | MEGANUCLEASE VARIANTS CLEAVING THE GENOME OF A PATHOGENIC NON-INTEGRATING VIRUS AND USES THEREOF - An I-CreI variant, wherein at least one of the two I-Cre1 monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the genome of a non-integrating virus, in particular herpes simplex virus (HSV) or Hepatitis B virus (HBV) for use in genome engineering and for in vivo and ex vivo (gene cell therapy) genome therapy as well as the treatment of a virus infection. | 11-05-2015 |
20150359746 | Technology for the Preparation of Microparticles - Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions. | 12-17-2015 |
20160017299 | OBLIGATE HETERODIMER VARIANTS OF FOKI CLEAVAGE DOMAIN - Disclosed are methods of making and using engineered Fold cleavage domain variants. Also disclosed are methods, compositions and fusion proteins containing obligate heterodimers of engineered Fold cleavage domain variants and DNA binding domains, such as zinc finger protein (ZFP) domains and transcription activator-like effector (TALE) domains. | 01-21-2016 |
20160046962 | COMPOSITIONS AND METHODS OF NUCLEIC ACID-TARGETING NUCLEIC ACIDS - This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof. | 02-18-2016 |
20160177278 | Cas9-DNA Targeting Unit Chimeras | 06-23-2016 |
20160186152 | MODIFIED CASCADE RIBONUCLEOPROTEINS AND USES THEREOF - A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualisation, transcriptional activation or repression. A pair of ribonucleotides fused to FokI dimers may be used to generate double-strand breakages in the DNA to facilitate these applications in a sequence-specific manner. | 06-30-2016 |
20160201040 | ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF | 07-14-2016 |